Clinical outcomes of patients with mitral prosthetic valve obstructive thrombosis treated with streptokinase or tenecteplase
Copyright © 2021 Cardiological Society of India. Published by Elsevier B.V. All rights reserved..
Agent of choice for thrombolytic therapy (TT) in prosthetic valve thrombosis (PVT) is unknown. 84 mitral obstructive-PVT episodes treated with TT (43: Tenecteplase; 41: Streptokinase) were included in this prospective study. The incidence of primary end-point (CCS: complete clinical success, defined as complete or partial hemodynamic success with no complications or surgery) was 84.5% with recurrent PVT as a sole predictor. Bleeding and embolic manifestations were noted in 8.3% and 4.7% of episodes respectively. Tenecteplase use was associated with lower complication rate and a mitral EOA of <0.74 cm2 at presentation predicts the need for extended thrombolysis (accuracy, 78.6%).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Indian heart journal - 73(2021), 3 vom: 22. Mai, Seite 365-368 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kiran, G Ravi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 3.4.- |
|---|
| Anmerkungen: |
Date Completed 20.10.2021 Date Revised 20.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ihj.2021.02.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327021705 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327021705 | ||
| 003 | DE-627 | ||
| 005 | 20231225195846.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ihj.2021.02.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1090.xml |
| 035 | |a (DE-627)NLM327021705 | ||
| 035 | |a (NLM)34154758 | ||
| 035 | |a (PII)S0019-4832(21)00046-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kiran, G Ravi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical outcomes of patients with mitral prosthetic valve obstructive thrombosis treated with streptokinase or tenecteplase |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.10.2021 | ||
| 500 | |a Date Revised 20.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Cardiological Society of India. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Agent of choice for thrombolytic therapy (TT) in prosthetic valve thrombosis (PVT) is unknown. 84 mitral obstructive-PVT episodes treated with TT (43: Tenecteplase; 41: Streptokinase) were included in this prospective study. The incidence of primary end-point (CCS: complete clinical success, defined as complete or partial hemodynamic success with no complications or surgery) was 84.5% with recurrent PVT as a sole predictor. Bleeding and embolic manifestations were noted in 8.3% and 4.7% of episodes respectively. Tenecteplase use was associated with lower complication rate and a mitral EOA of <0.74 cm2 at presentation predicts the need for extended thrombolysis (accuracy, 78.6%) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Prosthetic valve | |
| 650 | 4 | |a Prosthetic valve thrombosis | |
| 650 | 4 | |a Streptokinase | |
| 650 | 4 | |a Stuck valve | |
| 650 | 4 | |a Systematic review | |
| 650 | 4 | |a Tenecteplase | |
| 650 | 4 | |a Thrombolytic therapy | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Streptokinase |2 NLM | |
| 650 | 7 | |a EC 3.4.- |2 NLM | |
| 650 | 7 | |a Tenecteplase |2 NLM | |
| 650 | 7 | |a WGD229O42W |2 NLM | |
| 700 | 1 | |a Chandrasekhar, P |e verfasserin |4 aut | |
| 700 | 1 | |a Mohammad Ali, S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian heart journal |d 1961 |g 73(2021), 3 vom: 22. Mai, Seite 365-368 |w (DE-627)NLM000004162 |x 2213-3763 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2021 |g number:3 |g day:22 |g month:05 |g pages:365-368 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ihj.2021.02.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2021 |e 3 |b 22 |c 05 |h 365-368 | ||